← Leaderboards
Devin Thomas Wiley
Circumvent Pharmaceuticals, Inc.
$2,192,659
Attributed
$4,842,531
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,842,531 · 3
By mechanism
R44$4,136,457 · 1
R43$706,074 · 2
Top collaborators
- Robert David Steiner4 shared
- Daniel Chelsky2 shared
- Andrew Lim1 shared
Most similar at Circumvent Pharmaceuticals, Inc.
Same institution · by research overlap
- Andrew Lim$66,263
- Anna Ingrid Scott$152,394
Others in their field
Other Emerging Leaders on “Pharmacology”
- Leonard Freedman · Leidos Biomedical Research, Inc.$244,272,171
- Lynn Briscoe · Leidos Biomedical Research, Inc.$96,232,632
- Leonard Freedmand · Leidos Biomedical Research, Inc.$54,216,621
- Susan M Landau · University Of California Berkeley$47,252,026
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
- Michelle Lynn Sever · Rho Federal Systems Division, Inc.$26,732,375
Research focus
PharmacologyDoseHydroxylamineProteinsPharmaceutical PreparationsSmall MoleculeProgramsClinical TrialsNeurodegenerative DisordersExposure ToIn VivoClinical PracticeCln1 GeneMedicalPalliativeChildAdolescentGrantInfancyBenchmarkingBrain TissueChildhoodDiagnosisBrain
Grant awards (5)
Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating CLN1 Batten Disease$1,244,790
R44 · FY2025 · NS
Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL)$1,449,910
R44 · FY2022 · NS
Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL)$1,441,757
R44 · FY2021 · NS · contact PI
Alzheimer's Disease: simultaneous modulation of NMDAR, BACE1, APP and Fyn activity by palmitoylation-targeting CIRC825$507,284
R43 · FY2021 · AG · contact PI
Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL)$198,790
R43 · FY2017 · NS